Clinical Trials Logo

Clinical Trial Details — Status: Recruiting

Administrative data

NCT number NCT05494346
Other study ID # DEVALPO
Secondary ID
Status Recruiting
Phase N/A
First received
Last updated
Start date May 31, 2023
Est. completion date November 30, 2024

Study information

Verified date December 2023
Source Laboratoires Gilbert
Contact Carine BRUNEL
Phone +33 (0)1 45 39 50 21
Email cbrunel@labogilbert.fr
Is FDA regulated No
Health authority
Study type Interventional

Clinical Trial Summary

The purpose of this pre-market clinical investigation is to assess the safety and the performance of decongestant seawater spray pocket valve enriched with essential oils by Gilbert Laboratories. The study will evaluate the results of acute rhinitis associated with nasal obstruction using the decongestant seawaterspray pocket valve enriched with essential oils over a 8 day period.


Recruitment information / eligibility

Status Recruiting
Enrollment 101
Est. completion date November 30, 2024
Est. primary completion date November 30, 2024
Accepts healthy volunteers No
Gender All
Age group 12 Years and older
Eligibility Inclusion Criteria: - 1. Patient = 12 years. - 2. Patient with acute rhinitis associated with nasal obstruction during infectious episodes such as rhinopharyngitis (cold), rhinosinusitis, or during non-infectious episodes such as allergic rhinitis. - 3. a. Informed adult patient who has given written consent prior to any study specific procedure. b. Informed minor patient who has given assent and whose legal guardians have given written consent prior to any study-specific procedure. - 4. Patient able to meet the study requirements for monitoring, spray use, and questionnaire completion. - 5. Patient affiliated to a social security scheme. Exclusion Criteria: - 1. Pregnant and/or breastfeeding woman - 2. Hypersensitivity to seawater and/or known allergies to any of the ingredients of the spray. - 3. Diseases causing narrowing of the airways (e.g. asthma, chronic obstructive pulmonary disease (COPD)) and/or respiratory insufficiency. - 4. Patients with chronic nasal obstruction. - 5. Patients on local and systemic vasoconstrictors, local and systemic corticosteroids and antihistamines, non-steroidal anti-inflammatory drugs (NSAIDs), antibiotics and local antiseptics. - 6. Concomitant use of other nasal sprays, essential oils for local nasal use, nasal creams or gels. - 7. Patients under guardianship, curatorship or safeguard of justice.

Study Design


Intervention

Device:
Measurement of peak nasal flow.
Peak nasal flow measurements will be performed before and after the first use of the spray at D0, as well as after the use of the spray at the medical office at D3 (only for arm A).

Locations

Country Name City State
France Cabinet Médical Caen Caen
France Cabinet Médical Gainneville Gainneville

Sponsors (2)

Lead Sponsor Collaborator
Laboratoires Gilbert EVAMED

Country where clinical trial is conducted

France, 

Outcome

Type Measure Description Time frame Safety issue
Primary Performance of the Gilbert Laboratories pocket valve spray. Proportion of patient presenting a change of the symptom "nasal obstruction" by at least 1 pt, in the SNOT22 Test (item 22), between Day 0 (at inclusion in the office before use of the spray) and Day 3 (in the evening after last daily use of the spray).
This item is scaled from 0 to 5, 5 being the worst value.
From Day 0 to Day 3
Secondary Change of nasal obstruction between Day 0 and Day 3 Proportion of patients with a change in Peak Inspiratory Nasal Flow value of at least 30 L/min between Day 0 (before use of the spray) and Day 3 (after use of the spray) (arm A).
[0 - 350 L/min] 350 L/min means a better outcome.
From Day 0 to Day 3
Secondary Immediate change of nasale obstruction at D0 on first use (Arm A) Proportion of patients with a change in Peak Inspiratory Nasal Flow value of at least 30 L/min from pre- to post-spray measurements at Day 0 (arm A).
[ 0 - 350 L/min] 350 L/min means a better outcome.
At Day 0
Secondary Subjective feeling of reduced nasal obstruction on each day of use (arms A+B). Proportion of patients with a reduction in the symptom "nasal obstruction" of at least 1pt, on SNOT22 (Sino-Nasal Outcome Test 22), and on each day of use (from Day 0 to Day 6) (arms A+B).
This item is scaled from 0 to 5, 5 being the worst value.
From Day 0 to Day 6
Secondary Subjective feeling of nasal cavity cleansing (freshness) each day of use (arms A+B). Proportion of patients who experienced nasal cavity cleansing (feeling of freshness), on Patient Questionnaire, and on each day of use (from Day 0 to Day 6) (arms A+B). From Day 0 to Day 6
Secondary Subjective feeling of nasal secretion thinning on each day of use (arms A+B). Proportion of patients with a change in the symptom "thick nasal discharge" of at least 1pt, on SNOT22, and on each day of use (Day 0 to Day 6) (arms A+B).
This item is scaled from 0 to 5, 5 being the worst value.
From Day 0 to Day 6
Secondary Subjective feeling of relief of nasal irritation (mucous membrane) on each day of use (arms A+B). Proportion of patients who experienced relief of nasal (mucosal) irritation, on each day of use (Day 0 to Day 6) (arms A+B). From Day 0 to Day 6
Secondary Subjective feeling of relief of nasal itching on each day of use (arms A+B). Proportion of patients who experienced relief of nasal itching, on Patient Questionnaire, and on each day of use (Day 0 to Day 6) (arms A+B). From Day 0 to Day 6
Secondary Speed of action at which the patient feels (subjectively) a decrease in nasal obstruction at D0 and D3 (arms A+B). Proportion of patients with a change in immediate nasal obstruction after use of the spray, on Patient Questionnaire, at Day 0 and Day 3 (arms A+B). At Day 0 and Day 3
Secondary Speed of action at which the patient feels (subjectively) a purification of his nasal cavities (sensation of freshness) at D0 and D3 (arms A+B). Proportion of patients who experienced immediate nasal cleansing (feeling of freshness) after use of the spray at Day 0 and Day 3 (arms A+B). At Day 0 and Day 3
Secondary Improvement in the patient's quality of life after 7 days of use (arms A+B). Proportion of patients who experienced an improvement in quality of life, defined as an increase of at least 1pt on a scale of 0-10 between Day 0 and Day 6 (A+B arm).
10 mean a better value.
From Day 0 to Day 6
Secondary Patient satisfaction with the medical device after 7 days of use (arm A+B). Proportion of patients satisfied with the medical device, on a 4-point scale, at Day 6 (arm A+B).
The better value is "very satisfied" and the worst value is "very unsatisfied".
At Day 6
Secondary Facility of use of the medical device after 7 days of use (arm A+B) Proportion of patients who would recommend the medical device at Day 6 (arms A+B). At Day 6
Secondary Evolution of the overall severity of symptoms (arm A+B). Mean SNOT22 score on each day. Comparison of SNOT22 score at Day 3 versus Day 0 baseline (arms A+B).
[ 0 to 220 ] 0 is the better value.
At Day 0 and Day 3
Secondary All adverse events reported by patients using the pocket valve spray after 7 days of use (arm A+B). All adverse events reported by the patient during the study (arm A+B). From Day 0 to Day 7
Secondary Sensations of tingling and transient irritation (arms A+B). Proportion of patients with at least 1 adverse event between 1st and last use of the medical device among the following adverse events (arms A+B):
Tingling sensations
Sensations of transient irritation
From Day 0 to Day 6
See also
  Status Clinical Trial Phase
Recruiting NCT05080322 - Efficacy and Safety of On-demand and Continuous Administration of Nasal Spray in the Treatment of Allergic Rhinitis Phase 4
Recruiting NCT06028490 - A Study of IL4Rα Monoclonal Antibody in Patients With Uncontrolled Seasonal Allergic Rhinitis. Phase 2
Completed NCT04388358 - Traditional Chinese Medicine for the Treatment of Perennial Allergic Rhinitis on Gut Microbiota and Immune-modulation N/A
Recruiting NCT04202263 - Assessment of Suppression of Cutaneous Allergic Responses and Pruritis by Topical Minocycline Phase 2
Completed NCT04078009 - Standardising Nasal Allergen Challenge in Adult With Hay Fever N/A
Completed NCT03644680 - Changes in Adaptive Immune Responses and Effector Cell Responses Upon Nasal Allergen Exposure - a Pilot Study N/A
Completed NCT04541004 - Adolescent Mite Allergy Safety Evaluation Phase 3
Recruiting NCT05378594 - HDM and Silver Birch NAC Standardisation N/A
Not yet recruiting NCT05684380 - Efficacy and Safety of MAZ-101 in the Treatment of Persistent Allergic Rhinitis (PER) Phase 3
Completed NCT02910401 - Clinical Response to Rhinovirus Challenge Phase 2
Completed NCT02943720 - ATIBAR - Efficacy and Safety of Two Doses of AllerT in Patients Allergic to Birch Pollen Phase 2
Not yet recruiting NCT01014325 - Safety and Efficacy Study With Allergen Extracts of House Dust Mites for Specific Sublingual Immunotherapy Phase 3
Completed NCT02556801 - Efficacy and Safety of SUBLIVAC Phleum for Immunotherapy of Grass Pollen-Allergy Phase 2
Not yet recruiting NCT02233426 - Effect of Hypertonic Solutions on Allergic Rhinitis Patients N/A
Completed NCT02352168 - Airway Inflammation in Children With Allergic Rhinitis and Intervention N/A
Completed NCT01946035 - Alpha-Blockers in Allergic Rhinitis (MAN 01) Phase 4
Completed NCT01918956 - PURETHAL Birch RUSH Study Phase 4
Completed NCT01682070 - SUBLIVAC FIX Phleum Pratense DT/DRF Phase 2
Recruiting NCT01454492 - The Relationship Between Allergic Rhinitis and Geographic Tongue N/A
Completed NCT01438463 - PURETHAL® Mites Dose Range Finding Study in Patients With Persistent Allergic Rhinitis/Rhinoconjunctivitis Phase 2